Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats

Restenosis and destructive vascular remodeling are the main reasons for treatment failure in patients undergoing percutaneous coronary intervention (PCI). In this study, we explored the efficacy of magnolol (a traditional Chinese medicine) in the treatment of restenosis. The results of this study showed that the activities of thrombin and PAR-1 (protease-activated receptor 1) were significantly decreased by the treatment of magnolol. Based on protein docking analysis, magnolol exhibits its potential to bind to the PAR-1 active site. In addition, thrombin-induced connective tissue growth factor (CTGF) expression and the upstream of CTGF such as JNK-1 (but not JNK-2), c-Jun, and AP-1 were distinctly inhibited by magnolol (50 μM) in vascular smooth muscle cells (VSMC). For the functional assay, magnolol (50 μM) significantly inhibited the migration of VSMC, and rats treated with magnolol (13 mg/kg/day) after balloon angioplasty has observed a significant reduction in the formation of common arterial neointima. In conclusion, we identified a novel mechanism by which magnolol acts as the thrombin activity inhibitor and may be the PAR-1 antagonist. In accordance with these functions, magnolol could decrease thrombin-induced CTGF expression in VSMCs via PAR-1/JNK-1/AP-1 signaling.

• Publication year

  2020

• Venue

  Applied Sciences

• Publication date

  2020-12-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/app10238729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CTGF induces tenogenic differentiation and proliferation of adipose‐derived stromal cells

  2019cited by this paper
• Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction

  2019cited by this paper
• Insights on the Multifunctional Activities of Magnolol

  2019cited by this paper
• JNK and cardiometabolic dysfunction

  2019cited by this paper
• Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer

  2018cited by this paper
• Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts

  2018cited by this paper
• Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics

  2017cited by this paper
• Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia

  2017cited by this paper
• Targeting PAR1: Now What?

  2017influential reference
• Linked magnolol dimer as a selective PPARγ agonist – Structure-based rational design, synthesis, and bioactivity evaluation

  2017cited by this paper
• Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice

  2016cited by this paper
• PAR-1 Antagonists: An Emerging Antiplatelet Drug Class

  2016cited by this paper
• Connective tissue growth factor stimulates the proliferation, migration and differentiation of lung fibroblasts during paraquat-induced pulmonary fibrosis

  2015cited by this paper
• Bone marrow-derived c-jun N-terminal kinase-1 (JNK1) mediates liver regeneration.

  2015cited by this paper
• Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

  2014cited by this paper
• Abstract 205: Risk of Intracranial Hemorrhage with Protease-activated Receptor-1 Antagonists

  2013cited by this paper
• Essential role of Pin1 via STAT3 signalling and mitochondria-dependent pathways in restenosis in type 2 diabetes

  2013cited by this paper
• Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.

  2013cited by this paper
• c-Jun N-terminal Kinase 1 (JNK1) Is Required for Coordination of Netrin Signaling in Axon Guidance*

  2012cited by this paper
• Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway

  2012cited by this paper
• Direct thrombin inhibitors.

  2011cited by this paper
• Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.

  2011influential reference
• GPCRs Revisited: New Insights Lead to Novel Drugs

  2011cited by this paper
• Vascular smooth muscle cell proliferation in restenosis.

  2011cited by this paper
• Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of Vascular Smooth Muscle Cells

  2011cited by this paper
• A prospective natural-history study of coronary atherosclerosis.

  2011influential reference
• Connective Tissue Growth Factor (CTGF) Is Essential for Self Renewal and Proliferation of Mesenchymal Stromal Cells (MSCs) and Affects Leukemia-Stromal Interactions.

  2010cited by this paper
• Signal transduction by protease‐activated receptors

  2010cited by this paper
• Thrombin induces endothelial arginase through AP-1 activation.

  2010cited by this paper
• The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

  2009cited by this paper
• Thrombin-Induced Connective Tissue Growth Factor Expression in Human Lung Fibroblasts Requires the ASK1/JNK/AP-1 Pathway1

  2009cited by this paper
• A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery.

  2009cited by this paper
• c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.

  2008cited by this paper
• Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.

  2007cited by this paper
• The roles of proteinase-activated receptors in the vascular physiology and pathophysiology.

  2007cited by this paper
• Herbal remedy magnolol suppresses IL‐6‐induced STAT3 activation and gene expression in endothelial cells

  2006cited by this paper
• Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery.

  2005cited by this paper
• Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation.

  2005cited by this paper
• AP-1 subunits: quarrel and harmony among siblings

  2004cited by this paper
• Extracellular Matrix Changes in Stented Human Coronary Arteries

  2004cited by this paper
• Magnolol induces apoptosis in vascular smooth muscle

  2003cited by this paper
• Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis.

  2001cited by this paper
• Proteinase-activated receptors.

  2001cited by this paper
• Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.

  2000cited by this paper
• Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets.

  1999cited by this paper
• AP-1 function and regulation.

  1997cited by this paper
• Human connective tissue growth factor is expressed in advanced atherosclerotic lesions.

  1997cited by this paper
• Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury.

  1997cited by this paper
• Thrombin Activates NF‐κB through Thrombin Receptor and Results in Proliferation of Vascular Smooth Muscle Cells: Role of Thrombin in Atherosclerosis and Restenosis

  1997cited by this paper
• Prolonged Thrombin Inhibition Reduces Restenosis After Balloon Angioplasty in Porcine Coronary Arteries

  1996cited by this paper
• Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.

  1996cited by this paper
• Thrombin and proliferation of vascular smooth muscle cells.

  1995cited by this paper
• Signal transduction by tumor necrosis factor mediated by JNK protein kinases

  1994cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

  1991cited by this paper
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Computational identification of marine-derived inhibitors of Cyclophilin D and Protease-Activated Receptor-1 for the treatment of ischemic disease.

  2026cites this paper
• Magnolol: Chemistry and biology

  2023cites this paper
• Special Issue “Nature or Synthetic Compounds for Treating Arterial Thrombosis and Ischemic Stroke”

  2022cites this paper
• Fault diagnosis of rolling bearings based on improved enhanced envelope spectrum

  2021cites this paper
• In-situ test on impact loads of a five-module 100% low-floor tram and the prediction of damage characteristics of a pile-plank-supported tram track

  2021cites this paper
• Flexural Effects Evaluation on Hybrid Joints Under Uniaxial Tensile Load

  2021cites this paper